Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02600234 · ClinicalTrials.gov registry record · NA

Reduce Lap-hf Randomized Trial I

A NA study of Heart Failure, sponsored by Corvia Medical.

Active
Registry status
NA
Development phase
44
Enrollment target
20
Study locations

NCT02600234: Active NA study of Heart Failure, sponsored by Corvia Medical.

NCT02600234 is a NA study of Heart Failure that is active but no longer recruiting, run by Corvia Medical. The registered enrollment target is 44 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02600234, a NA study of Heart Failure, is active but no longer recruiting, sponsored by Corvia Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
44 participants
Enrollment target
20
Study locations

Study Summary

A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure.

Conditions Studied

Interventions

  • DEVICE Inter-Atrial Shunt Device
  • OTHER Intracardiac Echo

Study Locations (20)

New York

  • Columbia University Medical Center/NewYork Presbyterian Hospital - New York
  • Mt. Sinai Hospital - New York
  • New York University - New York

Other

  • The Alfred Hospital - Melbourne
  • OLVZ Aalst - Aalst
  • UMC Groningen - Groningen

Illinois

  • Northwestern University - Chicago
  • Evanston Northshore Healthcare - Evanston

Louisiana

  • Cardiovascular Institute of the South - Houma
  • Ochsner Medical Center - New Orleans

Ohio

  • Ohio Health - Columbus
  • Ohio State University College of Medicine - Columbus

Arizona

  • University of Arizona College of Medicine - Tucson

Connecticut

  • Yale University - New Haven

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2015-12
Est. Completion 2026-08
Phase NA
Corvia Medical

4 total trials

What the registry record for NCT02600234 still lists

NCT02600234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Inter-Atrial Shunt Device is the first listed.

NCT02600234 names 20 study sites across 13 states, led by New York, Other, Illinois.

Frequently Asked Questions

What is clinical trial NCT02600234 about?

NCT02600234 is a clinical study titled "Reduce Lap-hf Randomized Trial I". A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure.

What is the current status of trial NCT02600234?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 44 participants. The study started on 2015-12. Estimated completion is 2026-08.

What conditions does trial NCT02600234 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT02600234?

The interventions under investigation include: Inter-Atrial Shunt Device (DEVICE), Intracardiac Echo (OTHER).

Who is sponsoring clinical trial NCT02600234?

This trial is sponsored by Corvia Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02600234 being conducted?

This trial has 20 study locations across Arizona, Connecticut, Illinois, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02600234's enrollment target sits among peer trials

44 298th of 397 higher than 100 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02600234, the US trial registry maintained by the National Library of Medicine. NCT02600234 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.